Bacterial RNA polymerase inhibitor

This page covers all Bacterial RNA polymerase inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting bacterial RNA polymerase beta subunit, Bacterial RNA polymerase (C. difficile), Bacterial RNA polymerase.

Targets

bacterial RNA polymerase beta subunit · Bacterial RNA polymerase (C. difficile) · Bacterial RNA polymerase · beta subunit of bacterial RNA polymerase

Phase 3 pipeline (4)

• Rifampin containing regimen · Nantes University Hospital · Infectious Diseases
  Rifampin inhibits bacterial RNA synthesis by binding to the beta subunit of bacterial RNA polymerase.
• PAR-101/OPT-80 · Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Infectious Disease
  PAR-101/OPT-80 is a non-systemic antibiotic that binds to bacterial RNA polymerase to inhibit Clostridioides difficile growth in the colon.
• Placebo matched to Rifampin · Hamilton Health Sciences Corporation · Infectious Diseases
  Rifampin is a bacterial RNA polymerase inhibitor.
• Standard dose rifampicin · Radboud University Medical Center · Infectious Diseases
  Rifampicin inhibits bacterial RNA synthesis by binding to the beta subunit of bacterial RNA polymerase.

Patent intelligence

• bacterial rna polymerase inhibitor patent landscape — aggregated cliff calendar, attackable patents, originator estates